Literature DB >> 28659324

Multimethod Longitudinal HIV Drug Resistance Analysis in Antiretroviral-Therapy-Naive Patients.

Aubin J Nanfack1,2,3, Andrew D Redd4,5, Jude S Bimela1,6, Genesis Ncham1,7, Emmanuel Achem1,7, Andrew N Banin1,8, Allison R Kirkpatrick4, Stephen F Porcella9, Lucy A Agyingi3,10, Josephine Meli3,11, Vittorio Colizzi2,12,13, Arthur Nádas14, Miroslaw K Gorny1, Phillipe N Nyambi1,15, Thomas C Quinn4,5, Ralf Duerr16.   

Abstract

The global intensification of antiretroviral therapy (ART) can lead to increased rates of HIV drug resistance (HIVDR) mutations in treated and also in ART-naive patients. ART-naive HIV-1-infected patients from Cameroon were subjected to a multimethod HIVDR analysis using amplification-refractory mutation system (ARMS)-PCR, Sanger sequencing, and longitudinal next-generation sequencing (NGS) to determine their profiles for the mutations K103N, Y181C, K65R, M184V, and T215F/Y. We processed 66 ART-naive HIV-1-positive patients with highly diverse subtypes that underlined the predominance of CRF02_AG and the increasing rate of F2 and other recombinant forms in Cameroon. We compared three resistance testing methods for 5 major mutation sites. Using Sanger sequencing, the overall prevalence of HIVDR mutations was 7.6% (5/66) and included all studied mutations except K65R. Comparing ARMS-PCR with Sanger sequencing as a reference, we obtained a sensitivity of 100% (5/5) and a specificity of 95% (58/61), caused by three false-positive calls with ARMS-PCR. For 32/66 samples, we obtained NGS data and we observed two additional mismatches made up of minority variants (7% and 18%) that might not be clinically relevant. Longitudinal NGS analyses revealed changes in HIVDR mutations in all five positive subjects that could not be attributed to treatment. In one of these cases, superinfection led to the temporary masking of a resistant virus. HIVDR mutations can be sensitively detected by ARMS-PCR and sequencing methods with comparable performances. Longitudinal changes in HIVDR mutations have to be considered even in the absence of treatment.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  ARMS-PCR; HIV; Sanger sequencing; drug resistance mutations; drug-naive patients; human immunodeficiency virus; longitudinal changes; next-generation sequencing; subtype diversity; superinfection; transmitted drug resistance

Mesh:

Substances:

Year:  2017        PMID: 28659324      PMCID: PMC5648714          DOI: 10.1128/JCM.00634-17

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  56 in total

1.  Identification of HIV superinfection in seroconcordant couples in Rakai, Uganda, by use of next-generation deep sequencing.

Authors:  Andrew D Redd; Aleisha Collinson-Streng; Craig Martens; Stacy Ricklefs; Caroline E Mullis; Jordyn Manucci; Aaron A R Tobian; Ethan J Selig; Oliver Laeyendecker; Nelson Sewankambo; Ronald H Gray; David Serwadda; Maria J Wawer; Stephen F Porcella; Thomas C Quinn
Journal:  J Clin Microbiol       Date:  2011-06-22       Impact factor: 5.948

Review 2.  Evolutionary pathways of transmitted drug-resistant HIV-1.

Authors:  Marieke Pingen; Monique Nijhuis; Johan A de Bruijn; Charles A B Boucher; Annemarie M J Wensing
Journal:  J Antimicrob Chemother       Date:  2011-04-18       Impact factor: 5.790

3.  The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings.

Authors:  Charles F Gilks; Siobhan Crowley; René Ekpini; Sandy Gove; Jos Perriens; Yves Souteyrand; Don Sutherland; Marco Vitoria; Teguest Guerma; Kevin De Cock
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

4.  Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS).

Authors:  C R Newton; A Graham; L E Heptinstall; S J Powell; C Summers; N Kalsheker; J C Smith; A F Markham
Journal:  Nucleic Acids Res       Date:  1989-04-11       Impact factor: 16.971

Review 5.  HIV-1 genotypic drug resistance testing: digging deep, reaching wide?

Authors:  Kristel Van Laethem; Kristof Theys; Anne-Mieke Vandamme
Journal:  Curr Opin Virol       Date:  2015-06-24       Impact factor: 7.090

6.  Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon.

Authors:  J Fokam; R Salpini; M M Santoro; V Cento; R D'Arrigo; C Gori; C F Perno; V Colizzi; A Nanfack; L C Gwom; G Cappelli; D Takou
Journal:  Arch Virol       Date:  2011-04-05       Impact factor: 2.574

7.  Therapy failure resulting from superinfection by a drug-resistant HIV variant.

Authors:  Marieke Pingen; Jan L Nouwen; Sander Dinant; Jan Albert; Mattias Mild; Johanna Brodin; Birgitte B Simen; Susan Walsh; Manfred Kayser; Marchina E van der Ende; Martin Schutten; Charles A B Boucher
Journal:  Antivir Ther       Date:  2012-07-31

8.  Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.

Authors:  Susan J Little; Simon D W Frost; Joseph K Wong; Davey M Smith; Sergei L Kosakovsky Pond; Caroline C Ignacio; Neil T Parkin; Christos J Petropoulos; Douglas D Richman
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

9.  A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK.

Authors:  Raphaël Mourad; François Chevennet; David T Dunn; Esther Fearnhill; Valerie Delpech; David Asboe; Olivier Gascuel; Stéphane Hue
Journal:  AIDS       Date:  2015-09-24       Impact factor: 4.177

10.  Persistence of HIV-1 transmitted drug resistance mutations.

Authors:  Hannah Castro; Deenan Pillay; Patricia Cane; David Asboe; Valentina Cambiano; Andrew Phillips; David T Dunn
Journal:  J Infect Dis       Date:  2013-07-31       Impact factor: 5.226

View more
  12 in total

1.  Development of a Versatile, Near Full Genome Amplification and Sequencing Approach for a Broad Variety of HIV-1 Group M Variants.

Authors:  Andrew N Banin; Michael Tuen; Jude S Bimela; Marcel Tongo; Paul Zappile; Alireza Khodadadi-Jamayran; Aubin J Nanfack; Josephine Meli; Xiaohong Wang; Dora Mbanya; Jeanne Ngogang; Adriana Heguy; Phillipe N Nyambi; Charles Fokunang; Ralf Duerr
Journal:  Viruses       Date:  2019-04-01       Impact factor: 5.048

2.  Antiretroviral Adherence, Elevated Viral Load, and Drug Resistance Mutations in Human Immunodeficiency Virus-infected Women Initiating Treatment in Pregnancy: A Nested Case-control Study.

Authors:  Landon Myer; Andrew D Redd; Elton Mukonda; Briana A Lynch; Tamsin K Phillips; Anna Eisenberg; Nei-Yuan Hsiao; Adam Capoferri; Alison Zerbe; William Clarke; Maia Lesosky; Autumn Breaud; James McIntyre; Daniel Bruno; Craig Martens; Elaine J Abrams; Steven J Reynolds
Journal:  Clin Infect Dis       Date:  2020-01-16       Impact factor: 9.079

3.  Outcomes of donor-derived superinfection screening in HIV-positive to HIV-positive kidney and liver transplantation: a multicentre, prospective, observational study.

Authors:  Tania S Bonny; Charles Kirby; Craig Martens; Rebecca Rose; Niraj Desai; Michael Seisa; Christos Petropoulos; Sander Florman; Rachel J Friedman-Moraco; Nicole A Turgeon; Diane Brown; Dorry L Segev; Christine M Durand; Aaron A R Tobian; Andrew D Redd
Journal:  Lancet HIV       Date:  2020-07-27       Impact factor: 12.767

Review 4.  Recent Advances in the Development of Integrase Inhibitors for HIV Treatment.

Authors:  Jay Trivedi; Dinesh Mahajan; Russell J Jaffe; Arpan Acharya; Debashis Mitra; Siddappa N Byrareddy
Journal:  Curr HIV/AIDS Rep       Date:  2020-02       Impact factor: 5.071

5.  Anti-V2 antibody deficiency in individuals infected with HIV-1 in Cameroon.

Authors:  Lily Liu; Liuzhe Li; Aubin Nanfack; Luzia M Mayr; Sonal Soni; Adam Kohutnicki; Lucy Agyingi; Xiao-Hong Wang; Michael Tuen; Yongzhao Shao; Maxim Totrov; Susan Zolla-Pazner; Xian-Peng Kong; Ralf Duerr; Miroslaw K Gorny
Journal:  Virology       Date:  2019-01-14       Impact factor: 3.616

6.  Low-Abundance Drug-Resistant HIV-1 Variants in Antiretroviral Drug-Naive Individuals: A Systematic Review of Detection Methods, Prevalence, and Clinical Impact.

Authors:  Herbert A Mbunkah; Silvia Bertagnolio; Raph L Hamers; Gillian Hunt; Seth Inzaule; Tobias F Rinke De Wit; Roger Paredes; Neil T Parkin; Michael R Jordan; Karin J Metzner
Journal:  J Infect Dis       Date:  2020-04-27       Impact factor: 5.226

7.  Immune Correlates of Disease Progression in Linked HIV-1 Infection.

Authors:  Michael Tuen; Jude S Bimela; Andrew N Banin; Shilei Ding; Gordon W Harkins; Svenja Weiss; Vincenza Itri; Allison R Durham; Stephen F Porcella; Sonal Soni; Luzia Mayr; Josephine Meli; Judith N Torimiro; Marcel Tongo; Xiaohong Wang; Xiang-Peng Kong; Arthur Nádas; Daniel E Kaufmann; Zabrina L Brumme; Aubin J Nanfack; Thomas C Quinn; Susan Zolla-Pazner; Andrew D Redd; Andrés Finzi; Miroslaw K Gorny; Phillipe N Nyambi; Ralf Duerr
Journal:  Front Immunol       Date:  2019-05-14       Impact factor: 7.561

8.  Near full genome characterization of HIV-1 unique recombinant forms in Cameroon reveals dominant CRF02_AG and F2 recombination patterns.

Authors:  Andrew N Banin; Michael Tuen; Jude S Bimela; Marcel Tongo; Paul Zappile; Alireza Khodadadi-Jamayran; Aubin J Nanfack; Iheanyi O Okonko; Josephine Meli; Xiaohong Wang; Dora Mbanya; Jeanne Ngogang; Miroslaw K Gorny; Adriana Heguy; Charles Fokunang; Ralf Duerr
Journal:  J Int AIDS Soc       Date:  2019-07       Impact factor: 5.396

9.  Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1.

Authors:  Jiehua Zhou; Daniel Lazar; Haitang Li; Xin Xia; Sangeetha Satheesan; Paige Charlins; Denis O'Mealy; Ramesh Akkina; Sheena Saayman; Marc S Weinberg; John J Rossi; Kevin V Morris
Journal:  Theranostics       Date:  2018-02-07       Impact factor: 11.556

10.  Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.

Authors:  Henry Dilonga Meriki; Kukwah Anthony Tufon; Damian Nota Anong; Pascal Nji Atanga; Irene Ane Anyangwe; Fidelis Cho-Ngwa; Theresa Nkuo-Akenji
Journal:  PLoS One       Date:  2019-11-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.